Form 4: VolitionRx Officer Reports Tax Withholding Stock Transaction
SEC Form 4 Filing
Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx, reports a transaction involving the withholding of shares to cover tax obligations upon the settlement of restricted stock units.
Summary
- On October 4, 2024, Jacob Vincent Micallef, the Chief Scientific Officer of VolitionRx Ltd, reported a transaction on SEC Form 4.
- The transaction involved the company withholding 5,200 shares of common stock at a price of $0.883 per share to cover tax obligations related to the settlement of 13,000 restricted stock units.
- Micallef directly owns 350,661 shares of VolitionRx common stock.
- He also indirectly owns 55,000 shares through his spouse and 38,113 shares through Borlaug Limited, where he is a controlling director.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a standard tax withholding transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine SEC filing related to insider transactions, specifically the withholding of shares for tax purposes, which is a common practice in equity compensation.
Key Dates
| Date | Description |
|---|---|
| 10/04/2024 | Date of the stock transaction (tax withholding). |
| 10/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.